Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
Financings

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

By The Northwire Desk — AI Analysis Mar 20, 2026 · 19:35 QNTM · 3.11 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Quantum BioPharma Ltd. has closed the initial tranche of its previously announced offering, issuing 3,750 Debenture Units for gross proceeds of $3,750,000 CAD.
  • The Company has also completed an initial batch of its Debt Settlement, issuing 370,457 Class B subordinate voting shares to settle approximately $1,117,727 CAD of debt owed to arm’s length creditors and insiders.
  • Both transactions involve related party participation (one director in the offering; insiders in the debt settlement) and rely on exemptions from formal valuation and minority shareholder approval requirements under Multilateral Instrument 61-101.

Key Details

  • Financing Tranche 1:
    • Instrument: 3,750 Debenture Units.
    • Gross Proceeds: $3,750,000 CAD.
    • Use of Proceeds: Ongoing development of the Company's business model and general working capital purposes.
    • Related Party Participation: One director subscribed for Debenture Units representing aggregate gross proceeds of $300,000 CAD.
    • Regulatory Status: Exemptions from MI 61-101 formal valuation and minority shareholder approval requirements relied upon (sections 5.5(a) and 5.7(1)(a)) as transaction value does not exceed 25% of market capitalization. No material change report filed 21 days prior to closing.
  • Debt Settlement:
    • Instrument: 370,457 Class B subordinate voting shares.
    • Debt Settled: Approximately $1,117,727 CAD owed to certain arm’s length creditors and insiders.
    • Related Party Participation: Insiders participated in the settlement.
    • Regulatory Status: Exemptions from MI 61-101 formal valuation and minority shareholder approval requirements relied upon. No material change report filed 21 days prior to closing.
  • Company Context:
    • Quantum BioPharma is a biopharmaceutical company focused on neurodegenerative, metabolic, and alcohol misuse disorders.
    • Lead compound: Lucid-MS (patented new chemical entity for myelin degradation).
    • Retains 25.71% ownership in Celly Nutrition Corp. (OTC version of UNBUZZD™) with a 7% royalty on sales until $250 million is reached, dropping to 3% thereafter.
    • Holds approximately C$130 million in tax loss carry-forwards.
Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other